EX-99.1

(A joint stock limited company incorporated in the People’s Republic of China with limited liability)

The Board wishes to announce that the Company proposes to enter into the Framework Agreement with China Life Capital by 31 May 2018, pursuant to which the Company will subscribe in the capacity of the limited partner for the Fund Products of which China Life Capital or any of its subsidiaries serves as the general partner, and/or the Fund Products of which China Life Capital serves as the manager.

CLIC, the controlling shareholder of the Company, currently holds approximately 68.37% of the issued share capital of the Company, and is a connected person of the Company. China Life Capital, an indirect wholly-owned subsidiary of CLIC, is an associate of CLIC and also a connected person of the Company. As such, the Transactions constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

Given that the applicable percentage ratios in respect of the annual caps for the subscription by the Company in the capacity of the limited partner of the Fund Products of which China Life Capital or any of its subsidiaries serves as the general partner are more than 0.1% but less than 5%, such transactions are subject to the reporting, announcement and annual review requirements, but exempt from the independent shareholders’ approval requirement under Chapter 14A of the Listing Rules. Given that the applicable percentage ratios in respect of the annual caps for the management fee charged by China Life Capital as the general partner or the manager of the Fund Products are less than 0.1%, the arrangement for the payment of management fee is exempt from the reporting, announcement, annual review and independent shareholders’ approval requirements under Chapter 14A of the Listing Rules.

Pursuant to the Framework Agreement, the Company will subscribe in the capacity of the limited partner for the Fund Products of which China Life Capital or any of its subsidiaries serves (including individually and jointly with third parties) as the general partner, and/or the Fund Products of which China Life Capital serves as the manager (including the fund manager and co-manager).

The Company will enter into specific agreements with the counterparties including China Life Capital (or its subsidiaries) in respect of the subscription of specific Fund Products, and such specific agreements shall be subject to the principles set out in the Framework Agreement. Upon execution of the specific agreements, the Company shall make its capital contribution as required by the payment notice of the general partner, and the date of payment of the capital contribution as required by the payment notice shall be no earlier than 10 working days after the issuance of such payment notice. The capital contribution to be made by the Company will be funded by the internal resources of the Company.

As the general partner or the manager of the Fund Products, China Life Capital (or its subsidiaries) will provide daily operation, investment management, and consulting and advisory services to the Fund Products. The management fee will be paid to the general partner or the manager in respect of the provision of such services on an annual or quarterly basis, which shall be borne by all the limited partners. The management fee to be borne by the Company as the limited partner shall be calculated based on the amount of its capital contribution to the Fund Products and with reference to the following fee rates:

If there is any independent third party subscribing for a Fund Product in the capacity of the limited partner simultaneously when the Company subscribes for the same Fund Product as the limited partner, and the amount of capital contribution by such independent third party accounts for 20% or more of the total capital contribution to the Fund Product by all the limited partners, then the management fee rate for the Fund Product borne by the Company shall match the rate available to the independent third party, but the annual management fee rate shall not exceed 1.5% in any event.

The investment scope of the Fund Products shall include real estate, warehousing logistics, apartments for long-term lease, urban renewal, infrastructure assets, corporate shareholdings in relation to the operation of such underlying assets and asset securitization products in relation to such assets (including, but not limited to, asset-backed securities, real estate investment trusts, quasi-real estate investment trusts, etc.), as well as other targets in which the Fund Products are permitted for investment. Other subscribers of the Fund Products shall be the leading enterprises in their industries, including large real estate developers, brand operators of commercial properties, brand operators of renowned apartments for long-term lease, enterprises with a leading market share in the warehousing logistics sector, and other partners having high-quality project resources within the investment scope described above.

The profits from the Fund Products shall be distributed to the Company as the limited partner in a way that is not inferior to the following principles of distribution and order of priority:

Upon signing by the parties, the Framework Agreement will take effect from 7 June 2018 and expire on 31 December 2019.

For the two years ending 31 December 2019, the annual caps for the subscription by the Company in the capacity of the limited partner of the Fund Products of which China Life Capital or any of its subsidiaries serves as the general partner, as well as the annual caps for the management fee charged by China Life Capital as the general partner or the manager of the Fund Products are as follows:

In determining the annual caps for the subscription of the Fund Products, the Company has taken into account the investment budgets of fund reserve projects and other projects for the years of 2018 and 2019 as provided by China Life Capital, as well as the needs of the Company for allocation of its asset portfolios.

In determining the annual caps for the management fee, the Company has taken into account its expected subscription amount of the Fund Products, and the fee rate of the management fee as set out in the Framework Agreement. In determining the fee rate of the management fee, the Company has made reference to the market standards and industry practices, including the prices of similar transactions with independent third parties, and the fee rates charged by fund managers in the real estate fund industry.

The Transactions can expand the sources of projects in connection with alternative investment of the Company, which will enable the Company to obtain the opportunities of assets allocation in the sectors of investment encouraged by the national policies such as apartments for long-term lease, urban renewal and logistics, as well as the sector of infrastructures, and to capture the investment projects with high potentials and returns. The assets within the investment scope of the Fund Products are highly resistant to inflation and may generally bring stable cash flow and/or future value appreciation. Further, given their weak correlation with other fixed income products and standardized investment products, such assets may play the role of risk diversification in investment portfolios. In addition, investment in the Fund Products can help extend the duration of the Company’s assets and narrow down the duration gap of assets and liabilities, which is in line with the development strategy of the Company for its investment business.

The Directors (including independent non-executive Directors) are of the view that the Transactions are conducted on normal commercial terms, are entered into in the ordinary and usual course of business of the Company, are fair and reasonable and in the interests of the Company and its shareholders as a whole, and that the annual caps of the Transactions are fair and reasonable. As Mr. Yang Mingsheng, Mr. Yuan Changqing, Mr. Liu Huimin and Mr. Yin Zhaojun hold positions in CLIC and/or China Life Capital, they have abstained from voting on the Board resolution to approve the Transactions.

The Company is one of the leading life insurance companies in the PRC. It offers personal insurance businesses, including life insurance, health insurance and accident insurance businesses, reinsurance relating to the above insurance businesses, use of funds permitted by applicable PRC laws and regulations or the State Council, as well as all types of personal insurance services, consulting business and agency business, sale of securities investment funds, and other businesses permitted by the CBIRC.

China Life Capital is a professional real assets fund management company, which considers real assets such as real estate and infrastructures as its investment targets and operates based on the model of private equity fund. Established in November 1995, China Life Capital has a registered capital of RMB1 billion and its principal business is investment management and asset management. As at 31 December 2017, the total assets of China Life Capital amounted to approximately RMB255,881,300 and its net assets amounted to approximately RMB233,824,000. China Life Capital was registered with the Asset Management Association of China as a private equity fund manager in September 2016, and satisfied the requirements of the CBIRC regarding the qualification of real estate investment management institution.

In this announcement, unless the context otherwise requires, the following expressions have the following meanings:


	RMB in million
	For the year ending 31 December 2018		For the year ending 31 December 2019
Annual cap for the subscription of the Fund Products by the Company		5,000		5,000
Annual cap for the management fee borne by the Company		150		200


Executive Directors:		Yang Mingsheng, Lin Dairen, Xu Hengping, Xu Haifeng

Non-executive Directors:		Yuan Changqing, Liu Huimin, Yin Zhaojun

Independent Non-executive Directors:		Chang Tso Tung Stephen, Robinson Drake Pike, Tang Xin, Leung Oi-Sie Elsie